106 related articles for article (PubMed ID: 29187703)
41. Pathological grading for predicting metastasis in phaeochromocytoma and paraganglioma.
Kimura N; Takayanagi R; Takizawa N; Itagaki E; Katabami T; Kakoi N; Rakugi H; Ikeda Y; Tanabe A; Nigawara T; Ito S; Kimura I; Naruse M;
Endocr Relat Cancer; 2014 Jun; 21(3):405-14. PubMed ID: 24521857
[TBL] [Abstract][Full Text] [Related]
42. Primary Renal Paragangliomas and Renal Neoplasia Associated with Pheochromocytoma/Paraganglioma: Analysis of von Hippel-Lindau (VHL), Succinate Dehydrogenase (SDHX) and Transmembrane Protein 127 (TMEM127).
Gupta S; Zhang J; Milosevic D; Mills JR; Grebe SK; Smith SC; Erickson LA
Endocr Pathol; 2017 Sep; 28(3):253-268. PubMed ID: 28646318
[TBL] [Abstract][Full Text] [Related]
43. Somatic mutations in H-RAS in sporadic pheochromocytoma and paraganglioma identified by exome sequencing.
Crona J; Delgado Verdugo A; Maharjan R; Stålberg P; Granberg D; Hellman P; Björklund P
J Clin Endocrinol Metab; 2013 Jul; 98(7):E1266-71. PubMed ID: 23640968
[TBL] [Abstract][Full Text] [Related]
44. Clinical Features and Risk Factors of Skeletal-Related Events in Genitourinary Cancer Patients with Bone Metastasis: A Retrospective Analysis of Prostate Cancer, Renal Cell Carcinoma, and Urothelial Carcinoma.
Owari T; Miyake M; Nakai Y; Morizawa Y; Itami Y; Hori S; Anai S; Tanaka N; Fujimoto K
Oncology; 2018; 95(3):170-178. PubMed ID: 29874673
[TBL] [Abstract][Full Text] [Related]
45. Co-Occurrence of Pheochromocytoma-Paraganglioma and Cyanotic Congenital Heart Disease: A Case Report and Literature Review.
Zhao B; Zhou Y; Zhao Y; Zhao Y; Wu X; Bi Y; Luo Y; Ji Z; Rong S
Front Endocrinol (Lausanne); 2018; 9():165. PubMed ID: 29719528
[TBL] [Abstract][Full Text] [Related]
46. Germline mutations and genotype-phenotype correlation in Asian Indian patients with pheochromocytoma and paraganglioma.
Pandit R; Khadilkar K; Sarathi V; Kasaliwal R; Goroshi M; Khare S; Nair S; Raghavan V; Dalvi A; Hira P; Fernandes G; Sathe P; Rojekar A; Malhotra G; Bakshi G; Prakash G; Bhansali A; Walia R; Kamalanathan S; Sahoo J; Desai A; Bhagwat N; Mappa P; Rajput R; Chandrashekhar SR; Shivane V; Menon P; Lila A; Bandgar T; Shah N
Eur J Endocrinol; 2016 Oct; 175(4):311-23. PubMed ID: 27539324
[TBL] [Abstract][Full Text] [Related]
47. Genetic status determines
Tiwari A; Shah N; Sarathi V; Malhotra G; Bakshi G; Prakash G; Khadilkar K; Pandit R; Lila A; Bandgar T
J Med Imaging Radiat Oncol; 2017 Dec; 61(6):745-752. PubMed ID: 28585398
[TBL] [Abstract][Full Text] [Related]
48. Role of positron emission tomography and bone scintigraphy in the evaluation of bone involvement in metastatic pheochromocytoma and paraganglioma: specific implications for succinate dehydrogenase enzyme subunit B gene mutations.
Zelinka T; Timmers HJ; Kozupa A; Chen CC; Carrasquillo JA; Reynolds JC; Ling A; Eisenhofer G; Lazúrová I; Adams KT; Whatley MA; Widimsky J; Pacak K
Endocr Relat Cancer; 2008 Mar; 15(1):311-23. PubMed ID: 18310297
[TBL] [Abstract][Full Text] [Related]
49. Cost of skeletal-related events in European patients with solid tumours and bone metastases: data from a prospective multinational observational study.
Hechmati G; Cure S; Gouépo A; Hoefeler H; Lorusso V; Lüftner D; Duran I; Garzon-Rodriguez C; Ashcroft J; Wei R; Ghelani P; Bahl A
J Med Econ; 2013; 16(5):691-700. PubMed ID: 23441975
[TBL] [Abstract][Full Text] [Related]
50. The cost of treatment of skeletal-related events in patients with bone metastases from lung cancer.
Delea T; Langer C; McKiernan J; Liss M; Edelsberg J; Brandman J; Sung J; Raut M; Oster G
Oncology; 2004; 67(5-6):390-6. PubMed ID: 15713995
[TBL] [Abstract][Full Text] [Related]
51. Surgical Treatment of Malignant Pheochromocytoma and Paraganglioma: Retrospective Case Series.
Strajina V; Dy BM; Farley DR; Richards ML; McKenzie TJ; Bible KC; Que FG; Nagorney DM; Young WF; Thompson GB
Ann Surg Oncol; 2017 Jun; 24(6):1546-1550. PubMed ID: 28058556
[TBL] [Abstract][Full Text] [Related]
52. Genetic testing in pheochromocytoma- and paraganglioma-associated syndromes.
Benn DE; Richardson AL; Marsh DJ; Robinson BG
Ann N Y Acad Sci; 2006 Aug; 1073():104-11. PubMed ID: 17102077
[TBL] [Abstract][Full Text] [Related]
53. Localization and prediction of malignant potential in recurrent pheochromocytoma/paraganglioma (PCC/PGL) using 18F-FDG PET/CT.
Fikri AS; Kroiss A; Ahmad AZ; Zanariah H; Lau WF; Uprimny C; Donnemiller E; Kendler D; Nordin AJ; Virgolini IJ
Acta Radiol; 2014 Jun; 55(5):631-40. PubMed ID: 24037430
[TBL] [Abstract][Full Text] [Related]
54. Extra-adrenal pheochromocytoma in the organ of Zuckerkandl: diagnosis and treatment strategies.
Kahraman D; Goretzki PE; Szangolies M; Schade H; Schmidt M; Kobe C
Exp Clin Endocrinol Diabetes; 2011 Jul; 119(7):436-9. PubMed ID: 21374546
[TBL] [Abstract][Full Text] [Related]
55. DNA Methylation Profiling in Pheochromocytoma and Paraganglioma Reveals Diagnostic and Prognostic Markers.
de Cubas AA; Korpershoek E; Inglada-Pérez L; Letouzé E; Currás-Freixes M; Fernández AF; Comino-Méndez I; Schiavi F; Mancikova V; Eisenhofer G; Mannelli M; Opocher G; Timmers H; Beuschlein F; de Krijger R; Cascon A; Rodríguez-Antona C; Fraga MF; Favier J; Gimenez-Roqueplo AP; Robledo M
Clin Cancer Res; 2015 Jul; 21(13):3020-30. PubMed ID: 25825477
[TBL] [Abstract][Full Text] [Related]
56. Clinical and pathological data of 10 malignant pheochromocytomas: long-term follow up in a single institute.
Huang KH; Chung SD; Chen SC; Chueh SC; Pu YS; Lai MK; Lin WC
Int J Urol; 2007 Mar; 14(3):181-5. PubMed ID: 17430251
[TBL] [Abstract][Full Text] [Related]
57. Pheochromocytoma in children.
Ciftci AO; Tanyel FC; Senocak ME; Büyükpamukçu N
J Pediatr Surg; 2001 Mar; 36(3):447-52. PubMed ID: 11226993
[TBL] [Abstract][Full Text] [Related]
58. Clinical and economic burden of bone metastasis and skeletal-related events in prostate cancer.
Yong C; Onukwugha E; Mullins CD
Curr Opin Oncol; 2014 May; 26(3):274-83. PubMed ID: 24626126
[TBL] [Abstract][Full Text] [Related]
59. Bone Metastases and Skeletal-Related Events in Medullary Thyroid Carcinoma.
Xu JY; Murphy WA; Milton DR; Jimenez C; Rao SN; Habra MA; Waguespack SG; Dadu R; Gagel RF; Ying AK; Cabanillas ME; Weitzman SP; Busaidy NL; Sellin RV; Grubbs E; Sherman SI; Hu MI
J Clin Endocrinol Metab; 2016 Dec; 101(12):4871-4877. PubMed ID: 27662441
[TBL] [Abstract][Full Text] [Related]
60. Clinical benefit of zoledronic acid in patients with lung cancer and other solid tumors: analysis based on history of skeletal complications.
Hirsh V; Tchekmedyian NS; Rosen LS; Zheng M; Hei YJ
Clin Lung Cancer; 2004 Nov; 6(3):170-4. PubMed ID: 15555218
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
